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INTRODUCTION 
 
 
Laryngeal cancer is a malignancy associated with significant psychosocial consequences as 
impairment of laryngeal function from disease and/or its treatment results in gross 
disturbances in breathing, speech, and swallowing with profound impact on the patient’s 
lifestyle and self esteem. The successful management of laryngeal cancer is dependent as 
much upon individualizing the plan of management to suit the particular patient and his/her 
expectations, as on close co-operation among members of a multidisciplinary team. 
 
EPIDEMIOLOGY 
 
World-wide Distribution 
 
The incidence of laryngeal cancer generally ranges from 2.5 to 17.2 per 100,000 per year. 
The highest incidence of laryngeal carcinoma has been reported from the Basque Country, 
Spain (20.4) and the lowest incidence for men from Qidong, China (0.1). Other areas of high 
incidence include Brazil (15.1) and North Thailand (18.4). European countries with a high 
incidence in males include France (15.6), Poland (11.9), and Italy (10.1). [1] 
 
INDIAN SCENARIO 
 
The globocan-2002 report showed that in India, carcinoma of the larynx constituted 6.1% of 
all cancers and is the fifth common malignancy in males while it is comparatively rare in 
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females. As per the Madras Metropolitan Tumour registry, the incidence rates in Chennai are 
3.3 per 100,000 males and 0.6 per 100,000 females. 
 
RISK FACTORS 
 
SMOKING 
 
Smoking is the major risk factor for laryngeal cancer. Tobacco smoke contains more than 30 
different carcinogenic agents such as polycyclic aromatic hydrocarbons and nitrosamines. A 
dose-dependent increase in risk of laryngeal cancer has been demonstrated in case-control 
studies; patients smoking more than 40 cigarettes a day are 13 times more likely to die of 
laryngeal cancer than non-smokers. [2] Smoking non-filter cigarettes [3] and/or black (air-
cured) tobacco [4] has been linked to higher risk due to the higher exposure to carcinogens. 
The extent of the role of passive or ‘second-hand’ smoking in cancer of the larynx is not 
clear. Apart from the aetiological role of tobacco smoking, its importance in prognosis of 
patients who develop laryngeal cancer is also relevant. It has been shown that patients who 
survive 3 years or more after treatment of laryngeal cancer and who continue to smoke are 
seven times more likely to develop a second primary cancer.  
 
ALCOHOL 
 
Epidemiological studies have proved the long-suspected association between chronic alcohol 
consumption and the risk of laryngeal cancer. While chronic alcohol consumption is an 
independent dose-dependent risk factor by itself, in conjunction with chronic tobacco use, the 
risk multiplies several folds. [5] Alcohol is presumed to act as a co-carcinogen and acts both 
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locally as well as systemically through various mechanisms at different stages during 
initiation and promotion. Carcinogenesis is also influenced by the malnutrition and depletion 
of protective vitamins and minerals that accompany chronic alcoholism. [6] 
 
AGE AND SEX DISTRIBUTION 
 
The age group most commonly affected is 50–70 years, women being affected at a younger 
age than males. The male to female ratio, which used to be heavily biased towards males at 
9:1, has come down to approximately 5:1, due to the increasing trend of smoking among 
females. In the United States, incidence rates continue to rise at 1.6% per year for white 
females while the corresponding rate in white males has decreased at 0.6% each year; the 
rates for both black men and women have been on the increase and the male:female ratio in 
this population has, therefore, not changed significantly. In patients younger than 35 years, 
however, the incidence in males and females is equal. [7] Another difference among the sexes 
is that supraglottic carcinoma is more frequent in women; according to one study 64% of 
laryngeal carcinomas were supraglottic in women against 46% in men. [8] 
 
ANATOMY  
 
The larynx is divided into the supraglottis, glottis, and subglottis. The supraglottis consists of 
the epiglottis, the false vocal cords, the ventricles, and the aryepiglottic folds, including the 
arytenoids. The glottis includes the true vocal cords and the anterior commissure. The line of 
demarcation between the glottis and supraglottis is the apex of the ventricle. The subglottis is 
located below the vocal cords and is considered to extend from a point 5 mm below the free 
margin of the vocal cord to the inferior border of the cricoid cartilage. 
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The supraglottis has a rich capillary lymphatic plexus; the trunks pass through the pre-
epiglottic space and the thyro-hyoid membrane and terminate mainly in the level II lymph 
nodes; a few drain to the level III lymph nodes. There are essentially no capillary lymphatics 
of the true vocal cords; as a result, lymphatic spread from glottic cancer occurs only if tumour 
extends to supraglottic or subglottic areas. The subglottis has relatively few capillary 
lymphatics. The lymphatic trunks pass through the crico-thyroid membrane to the pre-
tracheal (Delphian) lymph nodes in the region of the thyroid isthmus. The subglottis also 
drains posteriorly through the crico-tracheal membrane, with some trunks going to the 
paratracheal lymph nodes and others continuing to the inferior jugular chain. 
 
PATTERNS OF SPREAD  
 
LOCAL SPREAD 
 
Suprahyoid Epiglottis 
 
Lesions may grow like a mushroom, producing a huge exophytic mass with little tendency to 
destroy cartilage or spread to adjacent structures. Others may infiltrate and destroy cartilage 
and eventually amputate the tip. They tend to invade the vallecula, pre-epiglottic space, 
lateral pharyngeal walls, and the remainder of the supraglottis. 
 
Infrahyoid Epiglottis 
 
Lesions tend to produce irregular tumour nodules with invasion through the porous epiglottic 
cartilage into the pre-epiglottic space. They grow circumferentially to involve the false cords, 
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aryepiglottic folds, and, eventually, the medial wall of the pyriform sinus and the pharyngo-
epiglottic fold. Invasion of the anterior commissure and cords is usually a late phenomenon, 
and subglottic extension occurs only in advanced lesions. Lesions that extend onto or below 
the vocal cords are at a high risk for cartilage invasion, even if the cords are mobile. [9] 
 
False Cord 
 
Early false cord carcinomas usually have the appearance of a submucosal mass and are 
difficult to delineate accurately. They extend toward the thyroid cartilage and medial wall of 
the pyriform sinus. Extension to the infrahyoid epiglottis is common. Initial invasion of the 
vocal cord may occur submucosally and may be difficult to detect. Vocal cord invasion is 
often associated with thyroid cartilage invasion. Subglottic extension is uncommon. 
 
Aryepiglottic Fold and Arytenoid 
 
Early lesions are usually exophytic. As the lesions advance, they extend to adjacent sites and 
eventually cause laryngeal fixation due to invasion of the cricoarytenoid muscle and joint. 
Advanced lesions invade the base of the tongue, pharyngeal wall, and post-cricoid pharynx. 
 
Vocal Cord 
 
The majority of lesions begin on the free margin and upper surface of the vocal cord and are 
easily visible. When diagnosed, about two-thirds are confined to one cord, usually the 
anterior two-thirds of the cord. Extension to the anterior commissure is frequent. As the 
lesion enlarges, it extends to the ventricle, false cord, vocal process of the arytenoids, and 
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subglottis. Infiltrative lesions invade the vocal ligament and thyroarytenoid muscles, 
eventually reaching the thyroid cartilage. As cancers reach the cartilage, they tend to grow up 
or down the paraglottic space rather than invade cartilage. The conus elasticus initially acts as 
a barrier to subglottic extension. Advanced glottic lesions eventually invade through the 
thyroid cartilage or thyro-cricoid membrane to enter the neck and/or thyroid gland. 
 
Subglottic Larynx 
 
Subglottic cancers are uncommon. It is difficult to determine whether a tumour started on the 
undersurface of the vocal cord or in the subglottis with extension to the cord. They involve 
the cricoid cartilage early, because there is no intervening muscle layer. Cord fixation is 
common. 
 
LYMPHATIC SPREAD 
 
Supraglottic Carcinoma 
 
Cancers of the supraglottic larynx are significantly more likely to present with cervical nodal 
metastasis compared to other laryngeal subsites. The incidence of occult metastasis in 
supraglottic carcinoma ranges from 20% to 50% depending on the T stage of the primary. 
The overall rate of nodal metastasis is also related to the T stage. The primary echelons of 
nodal drainage are levels II, III and IV. In the clinically negative neck, micrometastases were 
found in 37% of patients with levels II and III being the most frequently involved. Occult 
metastases at levels I and V were found on pathological examination in only 6% and 1% 
respectively. [10] Within the supraglottis, tumours of the marginal zone, which includes the 
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suprahyoid epiglottis and the aryepiglottic folds, have a greater propensity to neck metastases 
compared to those of the infrahyoid epiglottis. The overall (occult and clinical) incidences of 
lymphatic metastasis in supraglottic carcinoma according to T-stage are T1 5–25%, T2 30–
55%, T3–T4 65–80%. [11] 
  
Glottic Carcinoma 
 
The risk of lymphatic metastases from carcinoma of the true vocal cords is relatively lower 
than that for supraglottic carcinoma. Since most early glottic cancers are treated using 
radiation therapy, the incidence of occult cervical metastasis has been reported only for 
surgically treated higher stage primaries, and ranges from 10% for T3 to 29% for T4 tumours. 
[12] The overall rate of metastasis is less than 5% for T1, 5–10% for T2, 10–20% for T3, and 
25–40% for T4 tumours. [13,14] The primary echelons of drainage are levels II, III and IV. 
As with other laryngeal tumours, isolated involvement of levels I and V is uncommon. 
Tumours of the vocal cords rarely metastasize bilaterally or into the contralateral neck except 
in the presence of extensive supra- or subglottic involvement or invasion of the thyroid 
cartilage. It is generally agreed that involvement of the Delphian node (which occurs in about 
10%) is associated with a poor outcome. [15] 
 
Subglottic Carcinoma 
 
The overall incidence of cervical lymphatic metastasis from primary subglottic carcinoma is 
less than 20%. The incidence of paratracheal node involvement is, however, much higher at 
50–65%. [16, 17] Mediastinal nodes may be involved in a high percentage of cases, with 
reported incidence of 46%. [18] 
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DISTANT METASTASIS 
 
The lung is the most commonly affected systemic site followed by the mediastinum, bone 
and liver. About 15% of patients with supraglottic cancers and 3% with glottis cancers will 
develop distant metastases within 2 years of diagnosis. [19] The development of distant 
metastases is generally preceded by locoregional failure, but one study has reported that 11% 
of supraglottic and 7% of glottic carcinomas developed distant metastases in the absence of 
local failure or neck recurrence. [20] 
 
PATHOLOGY 
 
Nearly all malignant tumours of the larynx arise from the surface epithelium and therefore are 
squamous cell carcinoma or one of its variants. Carcinoma-in-situ occurs frequently on the 
vocal cords. Differentiating among dysplasia, carcinoma-in-situ, squamous cell carcinoma 
with microinvasion, and true invasive carcinoma is difficult. Most vocal cord carcinomas are 
well- or moderately differentiated. In a few cases, an apparent carcinoma and sarcoma occur 
together, but most of these are actually a spindle-cell carcinoma. Verrucous carcinoma occurs 
in 1% to 2% of patients with carcinoma of the vocal cord. The histological diagnosis is 
difficult and must correlate with gross appearance of the lesion. Small cell neuroendocrine 
carcinoma is rarely diagnosed in the supraglottic larynx, but it should be recognized because 
of its biologic potential for rapid growth, early dissemination, and responsiveness to 
chemotherapy. Minor salivary gland tumours arise from the mucous glands in the supraglottic 
and subglottic larynx, but they are rare. [21] Even rarer are chemodectoma, carcinoid, soft 
tissue sarcoma, malignant lymphoma, or plasmacytoma. Benign chondromas and 
osteochondromas are reported, but their malignant counterparts are rare. 
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STAGING 
 
Stage of the disease is the most important prognostic factor in any head and neck cancer.  
 
The TNM staging of laryngeal cancers is as follows: 
 
Primary Tumour (T) 
 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
 
Supraglottis 
 
T1 Tumour limited to one subsite of supraglottis with normal vocal cord mobility  
T2 Tumour invades mucosa of more than one adjacent subsite of supraglottis or glottis or 
region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, or medial wall of 
pyriform sinus) without fixation of the larynx 
T3 Tumour limited to larynx with vocal cord fixation and/or invades any of the following: 
post-cricoid area, pre-epiglottic tissues, para-glottic space, and/or minor thyroid cartilage 
erosion (e.g., inner cortex) 
T4a Tumour invades through the thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or esophagus) 
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T4b Tumour invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
 
Glottis 
 
T1 Tumour limited to the vocal cord(s) (may involve anterior or posterior commissure) with 
normal mobility 
T1a Tumour limited to one vocal cord 
T1b Tumour involves both vocal cords 
T2 Tumour extends to supraglottis and/or subglottis, or with impaired vocal cord mobility  
T3 Tumour limited to the larynx with vocal cord fixation, and/or invades paraglottic space, 
and/or minor thyroid cartilage erosion (e.g., inner cortex) 
T4a Tumour invades through the thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or esophagus)  
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
 
Subglottis 
 
T1 Tumour limited to the subglottis  
T2 Tumour extends to vocal cord(s) with normal or impaired mobility 
T3 Tumour limited to larynx with vocal cord fixation 
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T4a Tumour invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap 
muscles, thyroid, or esophagus)  
T4b Tumour invades prevertebral space, encases carotid artery or  mediastinal structures 
 
Regional Lymph Nodes (N)  
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in 
greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest 
dimension 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in 
greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest 
dimension 
N3 Metastasis in a lymph node, more than 6 cm in greatest dimension 
 
Distant Metastasis (M) 
 
MX Distant metastasis cannot be assessed 
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M0 No distant metastasis 
M1 Distant metastasis 
 
STAGE GROUPING 
 
I                                               T1 N0 M0 
II                                          T2 N0 M0 
III                                          T3 N0 M0 
                                               T1-3 N1 M0 
IVA                                     T4a N0 M0 
                                            T4a N1 M0 
                                             T1-4a N2 M0 
IVB                                   T4b Any N M0 
                                           Any T N3 M0 
IVC     Any T Any N M1 [22] 
 
SYMPTOMS 
 
The common symptoms of laryngeal cancer are hoarseness, sore throat, stridor, dysphagia 
and odynophagia. Hoarseness is an early symptom of glottic cancer but may be seen later in 
advanced supraglottic or subglottic tumours signifying spread to the vocal cord, arytenoid or 
cricoarytenoid joint. Paraglottic spread can occur submucosally from these sites to produce 
hoarseness without any mucosal irregularity. Sore throat and dysphagia are more commonly 
associated with supraglottic tumours and odynophagia signifies involvement of the 
hypopharynx or base of tongue. Referred otalgia generally indicates base of tongue 
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involvement, but may also be seen in tumours that have extended into the neck through 
cartilage. Ulceration and bleeding from exophytic tumours may present as haemoptysis. 
Dyspnoea and stridor occur with bulky supraglottic tumours or in the presence of vocal cord 
fixation. A neck mass almost always indicates lymphatic metastasis but may result from 
direct extension of the tumour into the soft tissues of the neck. 
 
PHYSICAL EXAMINATION 
 
A complete physical examination includes an indirect laryngeal mirror examination, 
fiberoptic endoscopy, palpation of the neck for any neck nodes and for assessment of the 
spread of the primary tumour. Flexible fiberoptic endoscopes are now used routinely as a 
complement to the laryngeal mirror examination. The mirror often provides the best view of 
the posterior pharyngeal wall. The flexible fiberoptic laryngoscope is inserted through the 
nose and is useful in more difficult cases. Determination of the mobility of the vocal cords 
frequently requires multiple examinations because the subtle distinctions between mobile, 
partially fixed, and fixed cords are often challenging, apparently changing from examination 
to examination. A cord that appeared mobile to the surgeon before direct laryngoscopy may 
exhibit impaired motion or even fixation after biopsy. Ulceration of the infrahyoid epiglottis 
or fullness of the vallecula is an indirect sign of pre-epiglottic space invasion. Palpation of 
diffuse, firm fullness above the thyroid notch with widening of the space between the hyoid 
and the thyroid cartilages signifies invasion of the pre-epiglottic space. The pre-epiglottic fat 
space is a low-density area on the CT scan, and changes resulting from tumour invasion are 
easily seen. Post-cricoid extension may be suspected when the laryngeal click disappears on 
physical examination. Post-cricoid tumour may cause the thyroid cartilage to protrude 
anteriorly, producing a fullness of the neck. Invasion of the thyroid cartilage remains a 
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difficult clinical diagnosis. Localized pain or tenderness to palpation or a small bulge over 
one ala of the thyroid cartilage is suggestive. Histopathological diagnosis is by means of 
biopsy done at the time of direct laryngoscopy. The minority of patients who present in 
stridor may require an emergency tracheostomy followed by a direct laryngoscopy and 
biopsy. 
 
IMAGING STUDIES 
 
The appearance of the normal laryngeal cartilages can vary considerably, depending on the 
degree of ossification and the amount of fatty marrow in the ossified medullar space. In 
children, the CT density of the laryngeal cartilages is similar to soft tissue. The 
(endochondral) ossification of hyaline cartilage starts early, in the third decade of life. A high 
degree of variation exists between individuals. [23] The thyroid cartilage shows the greatest 
variability in ossification; its ossification may also occur in an asymmetrical fashion. The 
cricoid and arytenoids show less pronounced variability in ossification. The epiglottis and 
vocal process of the arytenoids are composed of yellow fibrocartilage; this type of cartilage 
usually does not ossify. 
 
Squamous cell carcinoma, originating from the mucosal lining, is the most common 
malignant tumour in the larynx. Mucosal abnormalities can be far better evaluated by the 
clinician than with even sophisticated imaging methods such as CT or MRI. However, these 
tumours have the tendency to spread submucosally, and this extension into the deep-lying 
tissue planes may be difficult to evaluate by clinical examination alone. It is recognized that 
clinical classification of laryngeal cancer is insufficient when compared with pathologic 
classification. [24] A marked improvement in accuracy is obtained when the results of CT or 
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MRI are added to the clinical findings [25, 26] Imaging is mainly of benefit in detecting deep 
soft tissue extension, such as in the pre-epiglottic space, the laryngeal cartilages, and base of 
tongue. Findings from imaging studies frequently result in an up classification of the disease. 
Criteria used for tumour involvement are abnormal contrast enhancement, soft tissue 
thickening, presence of a bulky mass, infiltration of fatty tissue even without distortion of 
surrounding soft tissue, or a combination of these. Any tissue thickening between the airway 
and the cricoid arch is considered to represent subglottic tumour. Several studies have 
compared the CT/MRI findings with the results of whole organ sectioning after total or 
partial laryngectomy, showing that both techniques are accurate methods to visualize 
laryngeal pathology. [27] These studies, correlating whole organ sectioning and imaging, 
have also revealed some pitfalls. Small foci of mucosal tumour may be difficult to detect or 
may be invisible, and associated inflammatory and edematous changes may cause over-
estimation of the tumour extent. Distortion of adjacent normal structures may mimic 
involvement by tumour. Gross cartilage invasion can be detected with CT. Due to the large 
variability in the ossification pattern of the laryngeal cartilages, CT often fails to detect early 
cartilage invasion. Non-ossified hyaline cartilage shows more or less the same density values 
as tumour on CT images. Demonstration of tumour on the extralaryngeal side of the cartilage 
is a reliable, but late sign of cartilage invasion. Asymmetrical sclerosis, defined as thickening 
of the cortical margin and/or increased medullary density, comparing one arytenoids to the 
other, or one side of the cricoid or thyroid cartilage to the other side, is a sensitive but non- 
specific finding on CT. [28] Erosion or lysis has been found to be a specific criterion for 
neoplastic invasion in all cartilages. Other signs, such as cartilaginous blow-out or bowing, a 
serpiginous contour or obliteration of the medullary space are not very reliable for cartilage 
invasion. The combination of several diagnostic CT-criteria for neoplastic invasion of the 
laryngeal cartilages seems to constitute a reasonable compromise: when extralaryngeal 
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tumours and erosion or lysis in the thyroid, cricoid and arytenoid cartilages was combined 
with sclerosis in the cricoid and arytenoid (but not the thyroid) cartilages, an overall 
sensitivity of 82%, an overall specificity of 79% and an overall negative predictive value of 
91% was obtained. [29] MRI was recommended to be the best method to determine the status 
of the cartilages in the presence of a laryngeal tumour. [30] MRI is a more sensitive 
technique than CT to detect cartilage abnormalities. Areas of cartilage abnormality will result 
in an increase in signal intensity on T2-weighted images and contrast-enhanced T1-weighted 
MRI images. However, due to its high sensitivity for intracartilaginous alterations, MRI will 
yield, in a considerable number of cases, a false positive result, as distinction between true 
cartilage invasion and reactive inflammation, edema, fibrosis or ectopic red bone marrow is 
not possible. [31] Peritumoral inflammatory changes without tumour invasion are common 
coincidental findings in laryngeal cartilages, especially in the thyroid cartilage. Hence the 
diagnosis of neoplastic invasion of the thyroid cartilage should be made carefully on MRI. 
 
SELECTION OF TREATMENT MODALITY 
 
The goals of treatment include cure with the best functional result and the least risk of a 
serious complication. Patients may be considered to be in an early group if the chance of cure 
with larynx preservation is high, a moderately advanced group if the likelihood of local 
control is 60–70% but the chance of cure remains good, and an advanced group if the chance 
of cure is moderate and the likelihood of laryngeal preservation is relatively low. The early 
group may be treated initially by radiation therapy (RT) or, in selected cases, by partial 
laryngectomy. The moderately advanced group may be treated with either RT with 
laryngectomy reserved for relapse, or by total laryngectomy with or without adjuvant 
postoperative RT. The obvious advantage of the former strategy is that there is a fairly good 
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chance that the larynx will be preserved. Although some patients may be rehabilitated with a 
tracheo-esophageal puncture after laryngectomy, only about 20% of patients use this device 
long term and the majority use an electronic larynx. [32] The advanced group is treated with 
total laryngectomy and neck dissection with or without adjuvant RT or RT and adjuvant 
chemotherapy. [33] Recent data indicates that induction chemotherapy probably does not 
improve the likelihood of loco-regional control and survival, whereas concomitant 
chemotherapy and RT results in an improved possibility of cure compared with RT alone. 
[33, 34, 35] There is a subset of patients with high volume, unfavourable, advanced cancers 
who may be cured by chemoradiation but have a useless larynx and permanent tracheostomy 
and/or gastrostomy. These patients are best treated with a total laryngectomy, neck 
dissection, and postoperative RT.  
 
GLOTTIC CANCER 
 
Early Vocal Cord Carcinoma 
 
In most centres, RT is the initial treatment prescribed for T1 and T2 lesions, with surgery 
reserved for salvage after RT failure. [36] The likelihood of lymph node metastases is low, so 
the RT portals include only the primary site with a margin. [37] Patients are treated with once 
daily fractions of 2.25 Gy to 63 Gy for T1–T2A cancers and 65.25 Gy for T2B tumours. [38, 
39] 
 
Although hemilaryngectomy or cordectomy produces comparable cure rates for selected T1 
and T2 vocal cord lesions, RT is generally preferred. [40] Supracricoid laryngectomy is a 
procedure designed to remove moderate-sized cancers involving the supraglottic and glottic 
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larynx. [41] The larynx may be removed with preservation of the cricoids and the arytenoid 
with its neurovascular innervation, and the defect is closed by approximating the base of the 
tongue to the remaining larynx. The oncologic and functional results of this procedure in 
selected patients are reported to be excellent. Transoral laser excision also may provide high 
cure rates for select patients with small, well-defined lesions limited to the mid-third of one 
true cord. [42] A small subset of transoral laser surgeons successfully uses this technique in 
moderately advanced cancers. [43] The major advantage of RT compared with partial 
laryngectomy is better voice quality. Partial laryngectomy finds its major use as salvage 
surgery in suitable cases after RT failure. 
 
Moderately Advanced Vocal Cord Cancer 
 
Fixed-cord lesions (T3) may be subdivided into relatively favourable or unfavourable lesions. 
Patients with unfavourable lesions usually have extensive bilateral disease with compromised 
airway and are considered to be in the advanced group. Patients with favourable T3 lesions 
have disease confined mostly to one side of the larynx, have a good airway, and are reliable 
for follow-up. Some degree of supraglottic and subglottic extension usually exists. The extent 
of disease and tumour volume, in particular, are related to the likelihood of control after RT. 
[44] The patient with a favourable lesion is treated with RT or a partial laryngectomy. [45, 
46] Most patients are not candidates for the latter and are irradiated. Recent data suggest that 
the likelihood of loco-regional control is better after some altered fractionation schedules 
compared with conventional once-daily RT. One preferred fractionation schedule is 74.4 Gy 
in 62 twice-daily fractions. [47, 33] Additionally, concomitant chemotherapy and RT has 
been shown to improve the likelihood of cure compared with RT alone. [34] The optimal 
chemotherapy regimen is unclear. The risk of subclinical regional disease is 20–30% so that 
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the clinically negative neck is electively irradiated. Follow-up examinations are 
recommended every 4–6 weeks for the first year, every 6–8 weeks for the second year, every 
3 months for the third year, every 6 months for the fourth and fifth years, and annually 
thereafter. Patients with unfavourable lesions are usually not cured with chemoradiation and 
those who are cured are less likely to have a functional larynx. Thus, the majority of these 
patients are best treated with a total laryngectomy. 
 
Advanced Vocal Cord Carcinoma 
 
Advanced lesions usually show extensive subglottic and supraglottic extension, bilateral 
glottic involvement, and invasion of the thyroid, cricoid, or arytenoid cartilage, or frequently 
all three. [48, 49] The airway is compromised, necessitating a tracheostomy at the time of 
direct laryngoscopy in ~30% of patients. Clinically positive lymph nodes are found in about 
25–30% of patients. The mainstay of treatment is total laryngectomy and neck dissection, 
with or without adjuvant RT. The indications for postoperative RT include close or positive 
margins, subglottic extension (>1 cm), cartilage invasion, perineural invasion, endothelial-
lined space invasion, extension of the primary tumour into the soft tissues of the neck, 
multiple positive neck nodes, extracapsular extension, and control of subclinical disease in 
the opposite neck. [50, 51] Concomitant chemotherapy is given with postoperative RT for 
patients with positive margins and/or extracapsular extension. The postoperative RT dose is 
as follows: negative margins 60 Gy in 30 fractions; microscopic positive margins 66 Gy in 33 
fractions; and gross residual disease 70 Gy in 35 fractions. The lower neck receives 50 Gy in 
25 fractions; the stoma is boosted to 60 Gy with electrons if there is subglottic extension. 
Intensity-modulated RT may be used to avoid a difficult low neck match. Preoperative RT is 
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indicated for patients who have fixed neck nodes, have had an emergency tracheostomy 
through tumour, or have direct extension of tumour involving the skin. 
 
SUPRAGLOTTIC CANCER 
 
Early and Moderately Advanced Supraglottic Lesions 
 
Treatment of the primary lesion for the early group is by RT or supraglottic laryngectomy, 
with or without adjuvant RT. [52] Approximately 50% of supraglottic laryngectomies 
performed are followed by postoperative RT because of neck disease and, less often, positive 
margins. Transoral laser excision is effective in experienced hands for small, selected lesions. 
[43] Total laryngectomy is rarely indicated as the initial treatment for this group of patients 
and is reserved for treatment failures. The decision to use RT or supraglottic laryngectomy 
depends on several factors, including the anatomic extent of the tumour, medical condition of 
the patient, physician(s) preference, and inclination of the patient and family. Extension of 
the tumour to the true vocal cord, anterior commissure, vocal cord fixation, and/or thyroid or 
cricoid cartilage invasion precludes supraglottic laryngectomy. The procedure may be 
extended to include the base of tongue if one lingual artery is preserved. Supracricoid 
laryngectomy is an option for lesions involving one or both vocal cords; at least one 
arytenoid must be preserved. Vocal cord fixation and/or cartilage destruction are relative 
contraindications to this procedure. 
 
Overall, about 80% of patients are treated initially by RT. Approximately half of the patients 
whose lesions are technically suitable for a supraglottic laryngectomy are not suitable for 
medical reasons (e.g., inadequate pulmonary status or other major medical problems). 
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Analysis of local control by anatomic site within the supraglottic larynx shows no obvious 
differences in local control by RT for similarly staged lesions. Primary tumour volume based 
on pre-treatment CT is inversely related to local tumour control after RT. [44] A large, bulky 
infiltrative lesion is a common reason to select supraglottic laryngectomy, as local control is 
probably improved compared to treatment with RT alone. 
 
The status of the neck often determines the selection of treatment of the primary lesion. 
Patients with clinically negative neck nodes have a high risk for occult neck disease and may 
be treated by RT or supraglottic laryngectomy and bilateral selective neck dissections (levels 
II–IV). If a patient has an early-stage primary lesion and N2b or N3 neck disease, combined 
treatment is frequently necessary to control the neck disease. In these cases, the primary 
lesion is usually treated by RT and concomitant chemotherapy. CT is obtained 4 weeks after 
RT, and neck dissection is added if the risk of residual cancer in the neck is thought to exceed 
5%; otherwise the patient is observed and a CT is repeated in 3 months. [53] If the same 
patient were treated with supraglottic laryngectomy, neck dissection, and postoperative RT, 
the portals would unnecessarily include the primary site as well as the neck. If the patient has 
early, resectable neck disease (N1 or N2a) and surgery is elected for the primary site, 
postoperative RT is added only because of unexpected findings (e.g., positive margins, 
multiple positive nodes, extensive perineural invasion, or extracapsular extension). The 
primary site and neck are treated to 55.8 Gy at 1.8 Gy/fraction; the involved neck is boosted 
to 60–70 Gy depending on the risk of residual disease. 
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Advanced Supraglottic Lesions 
 
Although a subset of these patients may be suitable for a supraglottic or supracricoid 
laryngectomy, total laryngectomy is the main surgical option. Selected advanced lesions, 
especially those that are mainly exophytic, may be treated by RT and concomitant 
chemotherapy with total laryngectomy reserved for RT failures. [35] For patients whose 
primary lesion is to be treated by a total or partial laryngectomy and who have resectable 
neck disease, surgery is the initial treatment, and postoperative RT is added if needed. If the 
neck disease is unresectable, preoperative RT is used. 
 
SUBGLOTTIC CANCER 
 
Primary cancers of the subglottic larynx are extremely rare (about 1% of laryngeal cancers) 
and generally present in an advanced stage.  They involve the cricoid cartilage in the early 
stage because there is no intervening muscle layer. Partial or complete fixation of one or both 
cords is common. Misdiagnosis or diagnostic delay is frequent. Apart from squamous 
cancers, other histological types like minor salivary gland tumours, cartilaginous tumours and 
soft tissue sarcomas may arise in this region. The subglottis is much more frequently invaded 
by glottic carcinoma, and  these should be distinguished from primary subglottic carcinoma. 
Early lesions are treated with radiation therapy, and advanced lesions are usually managed by 
total laryngectomy and postoperative radiation therapy. 
 
TECHNIQUES OF RADIATION THERAPY [54] 
RT techniques can be broadly stratified into conventional radiotherapy, 3-dimensional 
conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT). Definition 
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of the target volume and the normal tissues that must be protected is based on data obtained 
via treatment planning computed tomography (CT) for both the later techniques. 3D CRT 
employs forward treatment planning and is much like conventional 2-dimensional RT except 
that the treatment plans are based on CT-defined 3-dimensional anatomy rather than a 2-
dimensional radiograph and surface anatomy. It is still essential to check the relationship of 
the portals with the surface anatomy on the treatment table. In contrast with 3D CRT, inverse 
treatment planning is used with IMRT, which may yield a more conformal treatment plan, 
thus reducing the dose to normal tissues and thereby decreasing the likelihood of acute and 
late toxicity. One of the major disadvantages of IMRT is that, because the dose distribution is 
more conformal and the dose gradient much sharper, there may be an increased risk of 
developing a marginal recurrence. Additional disadvantages may include less homogeneous 
dose distribution, more beam “on-time” leading to increased total body dose due to scatter, 
increased treatment planning time for the physicists and radiation oncologists, and increased 
cost. Therefore, there must be a clear potential advantage for proceeding with IMRT in a 
particular patient. Some of the advantages are reduction in xerostomia, reduction in 
dysphagia and avoidance of a difficult low neck match.  
 
Glottic Larynx 
 
Stage T1–T2 
 
Because the risk of subclinical disease in the cervical lymphatics is remote, the portals are 
limited to the primary lesion. It is a common practice to treat early vocal cord cancer with a 
standard field size (5 x 5 cm2, 6 × 6 cm2). The patient is treated in the supine position with 
the neck extended and the head immobilized in an aquaplast mask. The physician at the 
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treatment machine checks the field each day according to palpable anatomic landmarks. This 
practice allows the treatment volume to be kept at a minimum, while virtually eliminating the 
risk of geographic miss. The patient is treated with parallel opposed 6-MV X-ray fields 
weighted 3:2 to the side of the tumour if it is lateralized. An anterior boost field is usually 
employed to deliver approximately 5–10% of the total dose to reduce the high dose 
distribution laterally. 60Co or 4-MV X-ray beams are ideal. The typical borders for a T1 N0 
cancer are the middle of the thyroid notch, the bottom of the cricoid cartilage, 1 cm posterior 
to the thyroid ala, and 1.5 cm anterior to the skin of the anterior neck. The portals may be 
modified depending on the precise extent of the tumour. The dose fractionation schedule is 
63 Gy in 28 once-daily fractions for T1–T2a cancers and 65.25 Gy in 29 fractions for T2b 
tumours. The prescribed dose is the minimum target dose (MTD). The maximum dose in the 
irradiated volume is typically less than 103%. 
 
Radiation treatment technique for carcinoma of glottic larynx, stage T1–T2 
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a For T1 cancer, the superior border of field usually is at mid-thyroid notch (height of 
notch typically is about 1.0 cm or slightly more in male adults). If ventricle or false vocal 
cords are minimally involved, top of notch (which corresponds to cephalad portion of thyroid 
lamina as palpated just off midline) is often selected; more advanced lesions call for greater 
superior coverage. If only anterior half of vocal cord is involved, posterior border is placed at 
back of midportion of thyroid lamina. If posterior portion of cord is involved, border is 1.0 
cm behind lamina. If anterior face of arytenoid is also involved, posterior border is placed 1.5 
cm behind cartilage. If no subglottic extension is detected, inferior border of irradiation portal 
is at bottom of cricoid arch as palpated at midline. Anteriorly, beam falls off (by 1.5 cm) over 
patient’s skin. 
 
b  Three-field technique (two lateral wedge fields and an anterior open field). Lateral 
fields are differentially weighted to the involved side. Anterior field, which usually measures 
4 × 4 cm2, is centred approximately 0.5 cm lateral to midline in patients with one cord 
involved and typically delivers about 5% of total tumour dose (usually on last two treatment 
days) after treatment from lateral portals is completed. Anterior portal is essentially reduced 
portal that centres high dose to the tumour. By appropriate field weightings, encompassing 
the tumour within 95–97% of maximum isodose line is possible. 
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Simulation film of a 6 × 6 cm2 field covering the glottis only 
for treatment of a T1 N0 M0 glottic tumour 
 
 
 
 
 
Stage T3–Favorable T4 
 
The initial portals for T3–T4 N0 true vocal cord cancer are as shown in figure. Patients 
selected for definitive RT have favourable low-volume cancers without significant cartilage 
destruction. Because of a 20–25% risk of subclinical involvement of the jugulodigastric 
(level II) or midjugular (level III) lymph nodes, these areas are electively treated with 45.6–
50 Gy MTD. A small low-neck portal treats the low jugular (level IV) lymph nodes with a 
50-Gy given dose (at Dmax) over a duration of 5 weeks. Primary fields are then reduced, and 
the treatment is continued to the final tumour dose with fields that are usually slightly larger 
than for early vocal cord cancer. Most patients receive 74.4 Gy MTD at 1.2 Gy twice a day 
with a minimum 6-hour interfraction interval. Care must be taken not to underdose tumour 
that extends anteriorly through the thyrocricoid membrane for patients with favourable T4 
27 
 
tumours who are treated with 6-MV X-rays. Patients with high-volume unfavourable tumours 
are usually not treated with RT alone or combined with concomitant chemotherapy because 
of a relatively low probability of cure with a functional larynx. 
 
Radiation treatment technique for carcinoma of glottic larynx, stage T3–T4 N0 
 
 
Patient is treated in the supine position, and the field is shaped with Lipowitz’s metal. 
Anteriorly, field is allowed to fall off. The entire pre-epiglottic space is included by 
encompassing the hyoid bone and epiglottis. The superior border (just above angle of 
mandible) includes jugulodigastric (level II) lymph nodes. Posteriorly, portion of spinal cord 
must be included within field to ensure adequate coverage of midjugular (level III) lymph 
nodes; spinal accessory (level V) lymph nodes themselves are at low risk of involvement. 
Lower border is slanted to facilitate matching with low-neck field and to reduce length of 
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spinal cord in high-dose field. Inferior border is placed at bottom of cricoid cartilage if patient 
has no subglottic spread; in presence of subglottic extension, inferior border must be lowered 
accordingly.  
 
Supraglottic Larynx 
 
RT alone produces high control rates for T1, T2, and low-volume T3 supraglottic cancers. 
Unfavourable T3 and T4 tumours are often treated with laryngectomy and adjuvant RT; those 
who receive definitive RT also receive concomitant chemotherapy. The treatment volume is 
similar, with the exception that the beam generally is not allowed to “fall-off” over the 
anterior skin surface, except in thin patients, those with very bulky lymphadenopathy that 
extends anteriorly, or those who have lesions involving the infrahyoid epiglottis near the 
anterior commissure. Shielding even a few millimeters of the anterior skin, subcutaneous 
tissues, and lymphatic vessels reduces the likelihood of desquamation (particularly in patients 
who receive concomitant chemotherapy) and may lessen the risk of serious laryngeal edema. 
The inferior border of the portal is adjusted according to disease extent. For a false cord or 
infrahyoid epiglottic cancer, the bottom of the cricoids cartilage is usually chosen. For an 
epiglottic tip cancer, the lower border may be placed at or above the level of the true cords, 
depending on the extent and growth pattern (infiltrative versus exophytic) of disease. If the 
neck is clinically negative and tumour does not extend beyond the larynx, only the level II 
and level III nodes are treated. If the base of the tongue or pyriform sinus is involved or if 
neck disease is extensive, the primary portal includes the entire jugular chain, spinal 
accessory chain (level V) and retropharyngeal nodes. In all situations, the low neck is treated 
with an anterior en face portal, the size and shape of which vary according to the N-stage and 
laterality of disease. 
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Postoperative Irradiation 
In this situation, the larynx has been removed. The primary fields are treated through lateral 
parallel opposed portals to include the anterior and posterior neck from the base of skull to 
the top of the tracheal stoma. Techniques with either anterior or anterior and posterior portals 
have the disadvantages of underdosage of lymph nodes at the base of the skull in the region 
of the mastoid and unnecessary irradiation of a large volume of brain tissue in the posterior 
cranial fossa. The field is reduced after approximately 45 Gy MTD so that the spinal cord is 
no longer in the treatment field; the dose to high-risk areas behind the plane of the spinal cord 
may be boosted with 8- to 10-MV electrons. The low-neck portal includes the stoma. The 
dose at Dmax in most patients is 50 Gy in 25 fractions. In patients at high risk for recurrence 
in the low neck (i.e., who have positive level IV nodes), a boost dose is occasionally given 
through a reduced field. In patients with subglottic extension, the dose to the stoma and 
peristomal tissues is boosted with electrons, usually 12 MV. The energy selected should be 
high enough to deliver an adequate dose to the tracheo-esophageal groove (level VI) lymph 
nodes. Cobalt-60 is the beam of choice because of its build up characteristics. Alternatively, 
4-MV or 6-MV X-rays may be employed. A petrolatum gauze bolus is placed on all scars and 
over drain sites. All scars, suture holes, and drain sites are treated with generous (2–3 cm) 
margins.  
 
Surgical Methods and Voice Rehabilitation [55] 
Stripping of the cord implies transoral removal of the mucosa of the edge of the cord. 
Cordectomy is an excision of the vocal cord and is usually performed via transoral laser. It is 
used for well-defined lesions of the midthird of the vocal cord. The major advantages of laser 
excision are that it requires a day, as opposed to the 5.5 weeks necessary for radiotherapy, 
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and irradiation may be reserved if the patient develops a second head and neck cancer. 
Hemilaryngectomy is a partial laryngectomy allowing removal of limited cord lesions with 
voice preservation. Restrictions include involvement of one cord and up to 5 mm of the 
opposite cord, partial fixation of one cord, and up to 9 mm of subglottic extension anteriorly 
and 5 mm posteriorly (to preserve the cricoid cartilage). Extension to the epiglottis, false 
cord, or interarytenoid area is a contraindication to hemilaryngectomy. One arytenoid may be 
sacrificed, but the vocal cord must be fixed in the midline to prevent aspiration. The patient 
must have adequate pulmonary function. More extensive open partial laryngectomies have 
been described, such as the supracricoid partial laryngectomy. 
 
The last surgical alternative is total laryngectomy with or without a neck dissection. The 
entire larynx is removed, the pharynx is reconstituted, and a permanent tracheostomy is 
required. There are several options to accomplish voice rehabilitation after total 
laryngectomy. Prosthetic devices (e.g., the Singer-Blom valve) have been developed for 
insertion into a tracheo-esophageal fistula; the prosthesis allows the patient to speak without 
aspiration. Voice rehabilitation was evaluated in 173 patients who underwent a total 
laryngectomy and postoperative irradiation at the University of Florida; 118 patients were 
evaluable 2 to 3 years after treatment and 69 patients were evaluated for 5 years or longer. 
Methods of voice rehabilitation at 2 to 3 years and 5 years or more after surgery were: 
tracheo-esophageal speech 27% and 19%; artificial (electric) larynx 50% and 57%; 
esophageal 1% and 3%; nonvocal 17% and 14%; and no data 5% and 7%, respectively. 
 
 
 
 
31 
 
RESULTS OF TREATMENT 
 
VOCAL CORD CANCER 
 
Surgical Results 
 
Garcia-Serra et al reviewed 10 series containing 269 patients with carcinoma-in-situ of the 
vocal cord treated with stripping; the weighted average 5-year local control and ultimate local 
control rates were 71.9% and 92.4%, respectively. Similarly, 10 series containing 177 
patients treated with carbon dioxide laser revealed the following weighted average 5-year 
local control and ultimate local control rates: 82.5% and 98.1%, respectively. [50] 
 
Thomas et al. reported on 159 patients who underwent an open partial laryngectomy at the 
Mayo Clinic between 1976 and 1986. Seventeen of 159 patients had in situ lesions; the 
remaining were T1 invasive carcinomas. Local recurrence developed in 11 patients (7%), and 
nine eventually required laryngectomy. Ten patients developed recurrent cancer in the neck, 
and distant metastases were observed in ten patients. [57] 
 
Hemilaryngectomy including the ipsilateral arytenoid was reported by Som for 130 cases of 
vocal cord carcinoma extending to the vocal process and face of the arytenoid. The cure rate 
was 74% for 104 patients with T2 lesions and 58% for 26 patients with T3 cancers. [58]  
 
Foote et al. reported on 81 patients who underwent a laryngectomy for T3 cancers at the 
Mayo Clinic between 1970 and 1981. Seventy-five patients underwent a total laryngectomy 
and six underwent a near-total laryngectomy; 53 received a neck dissection. No patient 
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underwent adjuvant radiotherapy or chemotherapy. The 5-year rates of local and regional 
control, cause-specific survival, and absolute survival were 74%, 74%, and 54%, 
respectively. 
 
Radiation Therapy Results 
 
Garcia-Serra et al. reviewed 22 series containing 705 patients with carcinoma-in-situ of the 
vocal cord treated with radiotherapy and observed that the weighted average 5-year local 
control and ultimate local control rates were 87.4% and 98.4%, respectively. 
 
The results of irradiation for 519 patients with T1 and T2 N0 squamous cell carcinoma of the 
vocal cord treated by irradiation are as follows: The ultimate local control rates were 98% for 
T1 lesions and 96% for T2 lesions. The local control rates with larynx preservation rates were 
95% for T1 lesions and 82% and 76% for T2A and T2B lesions respectively. The 5-year rates 
of neck control for 506 patients who received no elective neck treatment for the overall 
groups and for the subsets of patients who remained continuously disease free at the primary 
site were: T1, 99% and 100%; T2a, 95% and 97%; and T2b, 87% and 92%, respectively. [38] 
 
The results of definitive radiotherapy for patients with T3 glottic carcinomas are compared to 
those following surgery in a series of 118 patients treated at the University of Florida. [49] 
Hinerman et al recently updated the University of Florida experience and reported a 5-year 
local control rate of 63% for 87 patients with T3 glottic carcinomas. [59] The likelihood of 
local control after radiotherapy is related to primary tumour volume and cartilage sclerosis. 
Disease free rates for T4 glottic carcinomas have been reported in the ranges of 40-54% in 
various series. [60, 61, 62, 63] 
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Supraglottic Larynx Cancer 
 
The local control and cause specific survival rates after definitive radiotherapy in a series of 
274 patients treated between 1964 and 1998 at the University of Florida have been reported 
as 100% and 100% for stage I, 86% and 93% in stage II, 64% and 81% in stage III, 61% and 
50% in stage IVA. The likelihood of local control with a functional larynx is related to 
tumour volume; those with tumours less than or equal to 6 cc have a more favourable 
outcome than those with larger primary tumours. [64] Twelve of 274 patients (4%) were  
reported to have experienced a severe acute or late complications, and two patients (1%) died 
as a consequence. [59] Lee et al reported on 60 patients who underwent a supraglottic 
laryngectomy and modified neck dissection at the M. D. Anderson Cancer Centre between 
1974 and 1987; 50 of 60 patients (83%) received adjuvant postoperative radiotherapy. Local 
control was 100% and local and regional control was obtained in 56 of 60 patients (93%). 
The 5-year disease-free survival rate was 91%. Three of 60 patients (5%) required a 
completion laryngectomy for intractable expiration. [65] Ambrosch et al reported on 48 
patients treated with transoral laser resection for T1 N0 (12 patients) and T2 N0 (36 patients) 
supraglottic carcinoma. Twenty-six patients underwent a unilateral (11 patients) or bilateral 
(15 patients) neck dissection. Postoperative radiotherapy was administered to two patients 
(4%). The 5-year local control rates were 100% for pT1 cancers and 89% for pT2 
malignancies. The 5-year recurrence-free survival and overall survival rates were 83% and 
76%, respectively. [66] 
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Results with Induction Chemotherapy followed by Radiation 
 
Decker et al reported on 34 previously untreated patients who received 2 to 3 cycles of 
cisplatin and fluorouracil: 93% showed an objective clinical response and 63% a complete 
response. They also pointed out that tumours sensitive to chemotherapy were also sensitive to 
radiotherapy. The first clinical trial was done by the Department of Veterans Affairs 
Laryngeal Cancer Study Group (VALSG) on laryngeal cancers and the results marked a 
turning point in laryngeal cancer treatment. In that trial, 332 patients with laryngeal cancer 
were randomly divided into 2 groups: one group received complete laryngectomy and the 
other group underwent 2 cycles of cisplatin and 5-fluorouracil; if they responded well (partial 
or complete response) they received a third cycle of chemotherapy followed by radiotherapy, 
and if there was a lack of response, they then underwent a complete laryngectomy. It should 
be pointed out that 63% of the patients had supraglottic tumours and 57% a fixed hemilarynx. 
The survival rate was similar in both groups, but two-thirds of the survivors from the 
chemotherapy group preserved their larynx. [67] A similar trial was done in France with 2 
random groups: complete laryngectomy versus 3 cycles of cisplatin and fluorouracil followed 
by radiotherapy if the clinical response was over 80%, or directly undergoing a complete 
laryngectomy if the response was lower. In that trial all the tumours were T3 and all had a 
fixed hemilarynx (only 31% were supraglottic tumours). The 2-year survival rate was 
significantly better in the surgical group (84% and 69%) but 15 (42%) of the 36 patients from 
the chemotherapy group did not need surgery. [68] 
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Results with Concurrent Chemoradiation 
 
The use of chemotherapy and radiotherapy simultaneously is based on the facts that 
chemotherapy may act as a sensitizer for radiotherapy, while radiotherapy may increase the 
chemotherapy absorption by the tumour, as well as the spatial co-operation of the two. The 
MACH-NC meta-analysis findings show that CCR alone increased the 5-year survival rate by 
8%, while induction chemotherapy did not improve the survival rate. [35] Forastiere et al 
assigned patients with laryngeal cancer randomly to 3 groups: induction chemotherapy 
followed by radiotherapy if there was a response (as with the veterans trial), CCR (cisplatin 
on days 1, 22, and 43), or just radical radiotherapy. The updated 5 year results in 2006 are as 
follows: 84% rate of laryngeal preservation in the CCR group, 71% in the induction group 
(P=.0029) and 66% in the radiotherapy group (P=.0002), with no significant differences 
among the groups whether for overall survival rates or tumour-free rates. [34] One group 
from Spain has published results following hyperfractionated radiotherapy and concomitant 
cisplatin in patients with advanced cancer of the larynx and hypopharynx. There was grade 3-
4 mucositis in 68% of the cases. With an average follow-up time of 55 months, the overall 5-
year survival rate and the disease-free survival rate were 42% and 39%, respectively. Also, 
44% of the patients preserved their larynx. [69] Another group of researchers has presented 
results of CCR along with 2 cycles of cisplatin and fluorouracil in 127 cases of advanced oral 
cavity, oropharyngeal, laryngeal, and hypopharyngeal carcinomas. With an average follow up 
timeframe of 3 years, local control was 89%, without significant differences between 
locations and an 80% rate of organ preservation. The toxic effects of the treatment were 
important: 73% of the cases required gastrostomy, 60% lost over 5 kg, and half required 
additional hospital stays due to a variety of complications. [70] 
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TREATMENT OF RECURRENCES 
 
Most recurrences appear within 18 months, but late recurrences may appear after 5 years. The 
latter are likely second primary malignancies. The risk of metastatic disease in lymph nodes 
increases with local recurrence. [71] 
 
Recurrence after Radiation Therapy 
 
With careful follow-up, recurrence is sometimes detected before the patient notices a return 
of hoarseness. There is often minimal lymphedema for 1 to 2 months after irradiation, which 
usually subsides or stabilizes. An increase in edema, particularly if associated with 
hoarseness or pain, suggests recurrence, even if there is no obvious tumour. Fixation of a 
previously mobile vocal cord usually implies local recurrence, but the occasional patient has 
a fixed cord with an otherwise normal-appearing larynx and without evidence of recurrence.  
It may be difficult to diagnose recurrence if the tumour is submucosal. Generous, deep 
biopsies are required. If recurrence is strongly suspected, laryngectomy may rarely be advised 
without biopsy-confirmed evidence of recurrence. Positron emission tomography may be 
useful to distinguish recurrent tumour from necrosis. Radiation therapy failures may be 
salvaged by cordectomy, hemilaryngectomy, supracricoid partial laryngectomy, or total 
laryngectomy. Biller et al reported a 78% salvage rate by hemilaryngectomy for 18 selected 
patients in whom irradiation failed; total laryngectomy was eventually required in 2 patients. 
Only two patients died of cancer. These investigators offered guidelines for using 
hemilaryngectomy: Normal contralateral vocal cord, uninvolved arytenoid, subglottic 
extension not exceeding 5 mm, and mobile vocal cord. [72] Mendenhall et al reported on 14 
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patients irradiated for T1 or T2 vocal cord cancers and underwent a hemilaryngectomy after 
local recurrence and 8 were successfully salvaged. [38] 
 
Recurrence after Surgery 
 
The rate of salvage by irradiation for recurrences or new tumours that appear after initial 
treatment by hemilaryngectomy is about 50%. Lee et al reported seven successes among 12 
patients; one lesion was later controlled by total laryngectomy. [73] Total laryngectomy can 
be used successfully to treat hemilaryngectomy failures not suitable for radiation therapy. 
Irradiation can be used occasionally for patients with recurrence in the neck or stoma after 
total laryngectomy. 
 
Complications of Treatment 
 
Surgical 
 
Repeated stripping of the cord may result in a thickened cord and hoarse voice. Neel et al 
reported a 26% incidence of nonfatal complications for cordectomy. [74] Immediate 
postoperative complications included atelectasis and pneumonia, severe subcutaneous 
emphysema in the neck, bleeding from the tracheotomy site or larynx, wound complications, 
and airway obstruction requiring tracheostomy. Late complications included removal of 
granulation tissue by direct laryngoscopy to exclude recurrence, extrusion of cartilage, 
laryngeal stenosis, and obstructing laryngeal web. The postoperative complications of 
hemilaryngectomy include aspiration, chondritis, wound slough, inadequate glottic closure, 
and anterior commissure webs. The postoperative complications of total laryngectomy may 
38 
 
include operative death, haemorrhage, fistula, chondritis, wound slough, carotid rupture, 
dysphagia, and pharyngeal / esophageal stenosis. The complication rate following 
supraglottic laryngectomy is about 10%, including fistula formation, aspiration, chondritis, 
dysphagia, dyspnoea, and carotid rupture. [75] 
 
Radiation Therapy 
 
After irradiation, the quality and volume of the voice tend to diminish at the end of the day. 
Edema of the larynx is the most common sequel following irradiation for laryngeal cancers. 
Steroids have been used to reduce edema secondary to radiation effect after recurrence has 
been ruled out by biopsy. If ulceration and pain occur, antibiotics are used. Soft tissue 
necrosis leading to chondritis occurs in about 1% of patients. Soft tissue and cartilage 
necroses mimic recurrence with hoarseness, pain, and edema; a laryngectomy may be 
recommended in desperation for fear of recurrent cancer, even though biopsies show only 
necrosis. Mendenhall et al recorded serious complications after definitive radiotherapy in one 
of 291 patients with T1 true cord cancers and three of 228 with T2 glottic malignancies. [44] 
 
Chemotherapy 
 
Chemotherapy either as part of induction or concurrent regimens is associated with an 
increased toxicity profile. The commonly used agents are cisplatin, 5-fluorouracil and taxanes 
(docetaxol and paclitaxel) in various combinations and schedules. The commonly seen 
toxicities are nausea, vomiting, diarrhoea, myelosuppression, increased rates of mucosits, 
peripheral neuropathy and allergic reactions. The other toxicities are nephrotoxicity, 
ototoxicity, fluid retention, cardiac arrhythmias etc. 
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EVOLVING STRATEGIES 
 
Induction Chemotherapy incorporating Taxanes 
 
Taxanes constitute the newest and one of the most active classes of cytotoxic agents against 
squamous carcinoma of the head and neck. Both paclitaxel and docetaxel are active as single 
agents and can be combined with concurrent radiation. Both agents have been evaluated as 
components of induction chemotherapy. At the University of Chicago, weekly doses of 
carboplatin and paclitaxel were shown to be well tolerated and highly active.[76] Docetaxel 
has been evaluated as an induction therapy in combination with 5-FU and cisplatin (TPF) in a 
number of phase II trials revealing feasibility of administration and encouraging activity. 
Depending on the number of cycles given as induction therapy, response rates have ranged 
between 70% and 100%, with complete response rates as high as 50% [77-79]. TAX 323 
treated patients with unresectable disease. Single-modality RT to 70 Gy was delivered after 
induction. Three-year survival was 37% versus 26% (P=.02) favouring TPF. TAX 324 
compared the same TPF versus PF induction in patients with both resectable and unresectable 
disease but followed it with radiation and low-dose concurrent carboplatin. [80] The overall 
3-year survival rate was 71% versus 30% favouring TPF (P=.006), and the 3-year 
progression-free survival rate was 49% versus 37% (P=.004) in favour of TPF. Recent 
studies have begun to evaluate the effects of induction chemotherapy in the concomitant 
chemoradiotherapy setting. The rationale for these studies is that concomitant 
chemoradiotherapy increases survival through better locoregional control, whereas induction 
chemotherapy increases distant control. The Madrid trial used 3 cycles of concurrent bolus 
cisplatin (100 mg/m2) with conventionally fractionated irradiation after either TPF or PF 
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induction therapy.  [81] CR rates favoured TPF 33% versus 14% (P=.001). The investigators 
reported a 2-year survival, 66% versus 61% favouring TPF (P=.06). 
 
TARGETED THERAPIES 
 
The success of the phase III randomized study by Bonner et al that showed a significant 
improvement in survival with the addition of cetuximab to radiotherapy in patients with 
locally advanced head and neck squamous cell carcinoma (HNSCC) has been hailed as a 
landmark study for integrating targeted therapy with standard radiation treatment. [82] RTOG 
0234 is a recently completed study that examined the feasibility and efficacy of combining 
cetuximab with different CRT combinations (either concurrent weekly cisplatin or concurrent 
weekly docetaxel) in high-risk postoperative patients (positive primary site surgical margin 
and/or involved nodes and/or extracapsular extension). Preliminary toxicity data suggests an 
acceptable toxicity profile with either cisplatin or docetaxel. [83] Concepts under discussion 
at the RTOG include phase II trials that would evaluate induction chemotherapy followed by 
concurrent CRT or cetuximab plus RT. A similar design is being tested by the EORTC using 
their successful taxane–platinum–5-FU induction platform combined with cetuximab before 
CRT for locally advanced HNSCC patients. Combining gefitinib with induction 
chemotherapy before CRT has also been investigated with encouraging early outcomes at 1 
year. [84] The experimental arm of the ongoing RTOG trial 0522, “A Randomized Phase III 
Trial of Concurrent Accelerated Radiation and Cisplatin vs. Concurrent Accelerated 
Radiation, Cisplatin, and Cetuximab (C225) for Stage III and IV Head and Neck 
Carcinomas.” This trial will eventually enrol over 700 patients with primary endpoints of 
survival and locoregional control.  
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ADVANCES IN RADIOTHERAPY 
 
IMRT has made possible sparing of parotids and has reduced the incidence of xerostomia 
which has been a long term side effect of head and neck radiation. Another side effect is 
dysphagia and aspiration. Using current technologies, it is possible to reduce the radiation 
dose and the volume of critical structures involved in swallowing without compromising the 
target. Eisbruch et al in 2004 identified the Pharyngeal Constrictors as playing an important 
role. [85] By decreasing radiation to these structures using IMRT, researchers were able to 
reduce the incidence of aspiration and swallowing disorders. [86, 87] In a long-term follow- 
up of these patients, it was noted that dysphagia improved continuously through 2-year 
follow-up and the rate of grade 2-3 dysphagia was rare (2/107). Notably, pharyngeal transit 
time has not been lengthened compared with pre-therapy measurements in these patients, 
representing a potentially important improvement compared with previous data from patients 
treated with conventional RT. 
 
PET-CT IN TARGET CONTOURING and ADAPTIVE RADIOTHERAPY 
 
FDG-PET appears very promising since it provides smaller, more accurate and reproducible 
GTVs in comparison with CT or MRI (Daisne et al, 2004). [88] More important, refining the 
GTV delineation by means of FDG-PET imaging ultimately led to more optimal dose 
distributions within PTVs and surrounding tissues. (Geets et al) [89, 90] Indeed, the reduction 
of the primary tumour TVs allowed by such an approach translated into significant decreases 
of the volumes receiving the highest dose using either 3D-confromal RT [89] or IMRT with 
helical tomotherapy. [90] The impressive progresses achieved in imaging, dose calculation, 
and delivery techniques have recently opened avenues for new treatment opportunities such 
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as adaptive radiation therapy and dose-painting approaches. Adaptive radiation therapy 
consists of reassessing the tumour volume after a given dose of radiation has been delivered 
and boosting the residual imaged tumour. Preliminary studies have already demonstrated the 
feasibility and usefulness of such approaches in pharyngo-laryngeal SCC, and showed 
significant tumour shrinkages using both anatomical and functional imaging. [90] Selection 
of small volumes for dose escalation strategies, even more when high dose per fraction is 
prescribed such as in simultaneous integrated boost IMRT, is mandatory to prevent 
unacceptable damages of critical structures embedded within the boost volumes. Another 
appealing approach is the integration of biological information from molecular imaging 
modalities with the purpose of targeting radiation-resistant regions inside the tumour, such as 
high clonogen density, proliferation, or hypoxia, hypothesizing that the regionally variable 
radiosensitivity may require heterogeneous dose distribution to achieve optimal tumour 
control. This approach, termed “dose painting” by Ling [91], has already been investigated in 
HNSCC with various tracers (Chao et al, 2001; Lin et al, 2008b; Grosu et al, 2007; Madani et 
al, 2007; Vanderstraeten et al, 2006). [92-96] If imaging plays a growing role in the target 
definition in radiotherapy, it should be noted that the macroscopic modalities available will 
fail to depict subtle tumour extension, and, in particular, the mucosal extent of the disease. As 
shown by Daisne et al [88], if both CT/MRI and FDG-PET overestimated the GTV in most 
dimensions, all three imaging modalities failed in accurately assessing the mucosal invasion 
visualized on the macroscopic specimen. In this context, a careful physical examination, 
including endoscopy and palpation, still remains the best tool for the appreciation of the 
mucosal  extent of HNSCC. 
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ORIGIN OF THE PRESENT STUDY 
 
 
Advanced carcinoma of the larynx has traditionally been treated with total laryngectomy and 
addition of adjuvant radiation depending on the histopathology. Total laryngectomy is widely 
recognized as one of the surgical procedures most feared by patients. Of the modalities used 
for preservation of larynx in advanced carcinoma of larynx, concurrent chemoradiotherapy 
therapy has been reported to offer a significantly higher chance of larynx preservation than 
does radiation therapy alone or induction chemotherapy followed by radiation. With the 
incorporation of salvage total laryngectomy, overall survivals have been reported to be equal 
to that of an upfront total laryngectomy and adjuvant radiation. For most patients with T3 or 
T4 disease without tumour invasion through cartilage into soft tissues, a larynx-preservation 
approach is considered an appropriate, standard treatment option, and concurrent 
chemoradiotherapy is the most widely applicable approach. [97] This study analyses the 
treatment methods, results and larynx preservation rates in advanced carcinoma of the larynx 
in our population.   
 
. 
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AIM OF THE STUDY 
 
 
The aim of the study was to analyse the treatment methods, outcomes and laryngeal 
preservation rates achieved in advanced (stage III/IV) squamous cell carcinoma of the larynx.  
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PATIENTS AND METHODS 
 
One hundred patients registered at the Cancer Institute during the years 2006-2008 with 
advanced, stage III/IV (as per the  AJCC/TNM classification), squamous cell carcinoma of 
the larynx, who were taken up for treatment with curative intent, were included in this study. 
Patients who had already undergone treatment and presented with a residue or recurrence, 
those with distant metastasis, those with histological types other than squamous cell 
carcinoma as well as those with uncontrolled intercurrent disease (e.g., diabetes, 
hypertension, thyroid disease) and / or known chronic infection with HIV or viral hepatitis 
were not taken up for the study. 
 
PRE-TREATMENT WORK UP 
 
 
• Detailed History 
• Complete physical examination and documentation of the TNM staging as per AJCC 
classification 
• Indirect and direct laryngoscopy and biopsy 
• Complete haemogram and biochemistry 
• Serology (HBsAg, HCV, HIV) 
• Chest X-ray and ECG 
• Histo-pathological examination 
• CT scan of the local part 
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TREATMENT PROTOCOL 
 
After explaining the nature of the disease, options of treatment and the expected results and 
obtaining an informed consent the patients were treated by one of the following methods: 
 
• Surgery 
• Surgery followed by postoperative radiation 
• Concurrent chemoradiation 
• Radiation alone. 
 
Surgery was the treatment in 14 patients. Surgery with adjuvant radiation was the modality in 
38 patients. 27 patients received concurrent chemoradiation and 21 patients were treated by 
radiation alone. 
 
Total laryngectomy with addition of neck dissection as and where indicated was the surgical 
procedure done. Adjuvant radiation was decided after review of histopathological findings. 
The indications for use of adjuvant radiation were pT4 primary, N2 or N3 nodal disease, 
perineural invasion, vascular embolism, extracapsular nodal spread and/or positive margins. 
Concurrent chemo-radiation used radiation concurrently with one of the two following 
chemotherapy schedules: 
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Schedule -1                                                                                                                           
CDDP/5-FU  
CDDP 70 mg per m2 on D1 
5-FU 375 mg per m2 on D1-D3 
Cycle was repeated every 3 weeks 
 
Schedule -2 
Weekly CDDP 
CDDP 40 mg per m2 on D1 repeated every week to a maximum of 6 cycles 
 
 
RADIOTHERAPY SCHEDULE 
 
Radiotherapy was given using 6-MV X-rays to deliver a daily tumour dose of 200 
cGy/fraction, 5 fractions a week, to a total dose of 60-66 Gy in 6-6½ weeks. Conventional 
techniques were employed with the help of an X-ray simulator to ensure the accuracy of the 
fields. The most commonly used field arrangement was two parallel opposing lateral wedged 
fields. Field reductions and electron boost were used appropriately. Radiation was used as the 
sole modality in patients who were unsuitable or unwilling for surgery and/or chemotherapy. 
 
FOLLOW UP 
 
Complete response to therapy was assessed at the first follow-up, at 6 weeks from the 
completion of treatment, both clinically and endoscopically. Thereafter the patients were 
48 
 
followed up on a monthly basis for the first 6 months, at bi-monthly intervals up to one year 
and then once every three months up to three years. Patients are followed up once in 6 
months for the next two years and annually after five years.  
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RESULTS 
 
STAGE OF THE DISEASE 
 
There were a total of 100 cases included in this study. On analysis, the stage distribution was 
as follows: 56 patients had stage III and 44 patients had stage IV disease.  
56
44 Stage III 
Stage IV
 
NODAL STAGE 
 
The nodal distribution in the group was: N0 58 cases, N1 19 cases, N2 22 cases and one 
patient had N3 disease.  
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AGE DISTRIBUTION 
 
The age distribution of patients varied between 15 – 83 years and the peak incidence was in 
the 6th decade. 
 
 
 
 
 
SEX DISTRIBUTION 
  
There were 92 males and 8 females. 
92
8
MALES
FEMALES
 
51 
 
SYMPTOMATOLOGY 
 
The predominant symptoms in the patient population included hoarseness which was the 
predominant symptom seen in 73 patients, pain in 13 patients, dysphagia in 8 patients, stridor 
in 5 patients, and cervical lymphadenopathy in one patient. 
 
 
 
 
 
ADDICTION PATTERNS 
 
Smokers constituted 49 of the 100 patients while 31 of the 100 patients in the study were 
alcoholics. 
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STAGE CORRELATION 
 
The correlation between the clinico-radiologic pre-operative staging and the pathologic stage 
for the surgically treated cases were as follows. 5 patients who were pre-operatively staged 
IV were found to be pathologically stage III. Clinico-radiologic staging in 11 patients was 
stage III but pathologically they were found to have stage – IV disease . Both stages were the 
same in 36 patients. 
 
RESPONSE RATES 
 
The results are to be interpreted keeping in mind the fact that the study was not a randomised 
one. The response rates in the different patient groups are given below. 
 
ANALYSIS ON THE BASIS OF STAGE (III / IV) 
 
COMPLETE RESPONSE RATES 
 
 
 
Treatment 
 
Stage – III Stage – IV 
 
Radiation alone 
 
7/9 (77.8%) 7/12 (58.3%) 
 
Chemoradiation 
 
17/20 (85.0%) 7/7 
 
p-value 
 
ns 0.046 
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The complete response rates with respect to the type of chemotherapy 
 
 
Chemotherapy schedule 
 
Complete response Residue 
 
CDDP/5-FU 
 
20 2 
 
Weekly CDDP 
 
4 1 
 
(p-value ns) 
 
 
 
DFS RATES AT ONE YEAR 
 
 
Clinical Stage-wise 
 
 
Treatment 
 
Stage – III Stage – IV 
 
Radiation 
 
7/8* (87.5%) 5/10 (50.0%) 
 
Chemoradiation 
 
16/18* (88.9%) 7/7 
 
Surgery 
 
8/8** 4/6** (66.7%) 
 
Surgery + Radiation 
 
10/15 (66.7%) 15/17 (88.2%) 
* This includes one failure each in the radiation and chemoradiation group which could 
be salvaged by surgery and both patients are disease free. 
**  One failure in both stage III and stage IV could be salvaged with radiation. 
(p-value for radiation versus chemo-radiation in stage IV was significant (0.025)) 
(p-value for radiation versus chemo-radiation was not significant in stage III) 
The surgically treated cases were analysed as per the pathological stage also and the results 
are as follows: 
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Pathological stage-wise 
 
 
 
Treatment 
 
Stage - III Stage - IV 
 
Surgery 
 
11/11* 1/3 (33.3%) 
 
Surgery + Radiation 
 
8/9 (88.9%) 17/23 (73.9%) 
 
p – value 
 
ns ns 
 
* This includes two failures salvaged by radiation. 
 
 
 
DFS RATES AT TWO YEARS 
 
 
 
Clinical Stage-wise 
 
 
Treatment Stage  - III  Stage  - IV  
Radiation 3/4 (75.0%) 2/5 (40.0%) 
Chemoradiation 7/8 (87.5%) 2/2 
Surgery 5/5 3/4 (75.0%) 
Surgery + Radiation 8/11 (72.7%) 9/12 (75.0%) 
 
(p-values for radiation versus chemoradiation for stage III and IV diseases not significant) 
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Pathological Stage-wise 
 
 
 
Treatment Stage  - III Stage - IV 
Surgery 8/8 0/1 
Surgery + Radiation 6/7 (85.7%) 11/16 (68.8%) 
p-value ns ns 
 
 
 
 
ANALYSIS ON THE BASIS OF ‘T’ STAGE (T3 / T4) 
 
 
 
The response rates were analysed with respect to the T3 / T4 status also and are as follows: 
 
 
 
COMPLETE RESPONSE RATES 
 
 
 
 
Treatment 
 
T3 T4 
 
Radiation alone 
 
7/10 (70.0%) 2/3 (66.7%) 
 
Chemoradiation 
 
16/17 (94.1%) --- 
 
p-value 
 
ns --- 
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DFS RATES AT ONE YEAR 
 
 
 
Clincal Stage-wise 
 
 
 
Treatment T3 T4 
Radiation 5/7 (71.4%) 2/3 (66.7%) 
Chemoradiation 15/16 (93.8%) --- 
Surgery 8/8 4/6 (66.7%) 
Surgery + Radiation 14/20 (70.0%) 10/11 (90.9%) 
 
(p-value ns for chemoradiation versus radiation) 
 
 
 
 
Pathological stage-wise 
 
 
 
Treatment T3 T4 
Surgery 11/11 1/3 (33.3%) 
Surgery + Radiation 11/13 (84.6%) 14/18 (77.8%) 
 
(p-value ns) 
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DFS RATES AT TWO YEARS 
 
 
 
Clinical stage-wise 
 
 
 
Treatment T3 T4 
Radiation 3/5 (60.0%) 1/1 
Chemo-radiation 7/8 (87.5%) --- 
Surgery 5/5 3/4 (75.0%) 
Surgery + Radiation 11/15 (73.3%) 6/8 (75.0%) 
 
(p-value ns for radiation versus chemo-radiation) 
 
 
 
 
Pathological stage-wise 
 
 
Treatment T3 T4 
Surgery 8/8 0/1 
Surgery + Radiation 9/11 (81.8%) 8/12 (75.0%) 
 
(p-value ns) 
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LARYNX PRESERVATION RATES 
 
The laryngeal preservation rates achieved were as follows: 
 
Concurrent chemo-radiation  – 23/27 (85.2%) 
Radiotherapy alone   – 13/21 (61.9%)  
(p-value (0.06) approaching statistical significance) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
DISCUSSION 
 
Laryngeal cancer is one of the most significant malignancies affecting human life because of 
the significant psychosocial consequences associated with the disease and its treatment. 
Squamous cell carcinoma is the predominant histological type and approximately 40% of 
patients will have stage III or IV disease when first evaluated. Most cases of laryngeal cancer 
are associated with a history of tobacco and/or alcohol use, so the treatment of patients is 
complicated by medical co-morbidity and the development of second primary cancers. Given 
the fundamental role the larynx plays in human speech and communication, determining the 
optimal management of laryngeal cancers must involve consideration of both survival and the 
functional consequences of a given treatment approach. The potential morbidity of curative 
treatment is a special consideration when total laryngectomy, either for primary therapy or as 
salvage treatment, is the recommendation. Total laryngectomy is widely recognized as one of 
the surgical procedures most feared by patients. Social isolation, job loss, and depression are 
common sequelae. Pioneering work on patient preferences showed that approximately 25% 
of healthy individuals interviewed were willing to trade a 20% absolute difference in survival 
for the opportunity to save their voice. [98] Different voice rehabilitations exist, [99] but 
many patients are dissatisfied with the results and report associated restrictions in their daily 
lives. Although the impact of the procedure on voice often receives the greatest attention, the 
presence of the stoma may adversely affect quality of life as much, if not more. [100] 
Accordingly, there has been keen interest in the development and refinement of organ 
preservation therapies, such as radiation therapy alone, the combination of chemotherapy and 
radiation therapy (concurrent/induction), and function-preserving partial laryngectomy 
procedures. With all three of these approaches, total laryngectomy is reserved for tumour 
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recurrence. Concurrent chemoradiotherapy has been reported to offer a significantly higher 
chance of larynx preservation than does radiation therapy alone or induction chemotherapy 
followed by radiation. All patients with T1-T2 laryngeal cancer should be treated, at least 
initially, with intent to preserve the larynx.T1-T2 laryngeal cancer can be treated with 
radiation or larynx-preservation surgery with similar survival outcomes. Local tumour 
recurrence after radiation therapy may be amenable to salvage by organ-preservation surgery, 
but total laryngectomy will be necessary for a substantial proportion of patients, especially 
those with T2 tumours. Concurrent chemoradiotherapy therapy may be used for larynx 
preservation for patients with stage II disease. For advanced carcinoma of the larynx , organ-
preservation surgery, concurrent chemoradiotherapy, and radiation therapy alone, all with 
further surgery reserved for salvage, offer potential for larynx preservation. All patients 
should be evaluated regarding their suitability for a larynx-preservation approach, and they 
should be informed of these treatment options. No larynx-preservation approach offers a 
survival advantage compared with total laryngectomy and appropriate adjuvant treatment. A 
minority of patients with T3-T4 disease will be suitable for specialized organ-preservation 
procedures, such as a supracricoid partial laryngectomy. The addition of postoperative 
radiation therapy will compromise anticipated functional outcomes. 
 
Reviewing our data of 100 patients with advanced carcinoma of the larynx, we found that 
42% of the patients had clinically positive neck nodes. This is in agreement with data 
reported in the literature. Lindberg et al reported 55% positive nodes in advanced supraglottic 
laryngeal malignancies [101] while Mendenhall et al reported 30% incidence in advanced 
glottic tumours. [38] The age and sex distribution and the addiction patterns also correlated 
with data in the literature which reports peak incidence in 50-70 years, a pre-dominant male 
predilection and association with smoking and alcohol. [102] Our study had 78 of the 100 
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cases in the age 50-70, 92/100 cases being males. With regards to the presenting symptoms 
the hoarseness was the presenting symptom in 73%, followed by pain, dysphagia, stridor and 
cervical lymphadenopathy which also correlate well with the reported data. [8] The 
correlation between pre-operative clinico-radiologic stage was 69% in our study, while the 
reported rates in the literature vary between 73% and 80%, with studies using MRI having 
higher accuracy. The most common error reported in the literature was in under-diagnosing a 
T4 disease which has been the most common error in our study also. [27] 
 
The complete response rates achieved in stage III were 77.8% and 85.0% with radiation and 
chemoradiation but this improvement did not attain statistical significance. The response rates 
in stage IV were 58.3% and 100% respectively. The p-value was statistically significant 
(0.046). 
  
The DFS rates at 1 year in stage III were 87.5% and 88.9% respectively with radiation and 
chemo-radiation; 100% and 88.9% for surgery alone and surgery with adjuvant RT 
respectively, when  analysed by their pathological stage. In stage IV disease, the rates were 
50% and 100% for radiation and chemo-radiation while the rates for surgery alone and 
surgery with adjuvant RT were 33.3% and 73.9% respectively. Statistical significance was 
achieved only for radiation versus chemo-radiation in stage IV (p-value-.025). 
 
The DFS rates at 2 years were 75.0%, 87.5%, 100% and 85.7% in stage III with radiation, 
chemo-radiation, surgery and surgery with adjuvant radiation, respectively. The 
corresponding rates were 40%, 100%, and 68.8% for radiation, chemo-radiation and surgery 
with adjuvant radiation in stage IV. None of the values at 2 years attained statistical 
significance. 
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The results, when T3 and T4 cases were analysed separately also, showed similar pattern with 
no statistical significance. 
 
The chemotherapy schedule used did not have any significant impact on the complete 
response rates. 
 
The larynx preservation rates achieved across the stages were 85% with chemo-radiation and 
61% with radiation alone. These results are comparable with data reported in the literature. 
Forastiere et al, in the RTOG 91-11 trial, reported 88% and 70% larynx preservation rates in 
the concurrent chemoradiation group and radiation group respectively. [34] The updated 5-
year results were reported as 84% and 61%. Lee et al, from MSKCC, reported 89% larynx 
preservation rates in locoregionally advanced carcinomas of the larynx and hypopharynx and 
an overall survival of 63% with concurrent chemoradiation. [103] Lambert et al reported 63% 
and 73% overall and disease-free survival at 3 years in patients treated with concurrent 
chemoradiation for locoregionally advanced carcinoma of larynx and hypopharynx. [104]  
 
The larynx preservation rates reported are summarised in the following table: 
 
 
Treatment 
 
Forastiere et al Lee et al Cancer Institute 
 
Radiation 
 
70% --- 61% 
 
Chemo-RT 
 
88% 89% 85% 
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The results from this study show that concurrent chemoradiation is an effective modality of 
treatment for advanced laryngeal cancer without any detrimental effect on survival while 
preserving the larynx in our population. Radiation alone can be an option for patients not 
suitable for chemotherapy but who are extremely motivated for larynx preservation but with 
lesser results. Randomised trials with larger number of patients are required to confirm the 
findings.  
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CONCLUSION 
 
Concurrent chemoradiation offers comparable oncological outcomes for patients with 
advanced carcinoma of the larynx while preserving their voice and thus offering a better 
quality of life. 
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